Aligning Science Across Parkinson's Logo Text
Submit site search
  • A549 PIP4P1 (TMEM55B) KO (CVCL_D3VW)

    By on

    A549 PIP4P1 (TMEM55B) CRISPR/CAS9 A549 knock-out cell line generated from parental A549 cells (ATCC A549 CCl-185) using CRISPR/Cas9 gene-editing technology. The cell line was verified by immunoblotting analysis and DNA-sequencing analysis. Used in publication: doi: https://doi.org/10.1101/2023.06.07.544051

  • mRNA purification by translating ribosome affinity purification (TRAP) of DAT-expressing cells (dopaminergic neurons) in mouse ventral midbrain

    By on

    This protocol describes the capture of eGFP-L10a-tagged ribosomes and mRNA from DAT-expressing cells (dopaminergic neurons) in mouse ventral midbrain.

  • Section 1: Enzymatic DNA Fragmentation (Manually)

    By on

    This protocol details manual enzymatic DNA Fragmentation prior to Section 2: NGS library preparation for sequencing.

  • Section 2: NGS library preparation for sequencing

    By on

    This protocol details NGS library preparation for sequencing and should be performed after Section 1: Enzymatic DNA Fragmentation (Manually).

  • Detection of accessible cholesterol in primary cilia using purified His-ALOD4-mNeon in 3T3 Fibroblasts

    By on

    The protocol described here is based upon previously established methods (Kinnebrew et al., 2019; Johnson and Radhakrishnan, 2021) and has also been used successfully to label cilia in RPE cells.

  • Section 3: Libraries quality control (QC)

    By on

    This protocol details quality control of libraries and should be performed after Section 2: NGS library preparation for sequencing.

  • Regional Mouse Brain Analysis (Modified QUINT)

    By on

    This is series of protocols that has been adapted from published and unpublished protocols broadly referred to as the QUINT workflow: QuPath visualization/segmentation QuickNII Brain Atlas Registration QMask Hemispheric Separation Visualign Transformation Nutil Data Integration QUINT Workflow Appendix QUINT Workflow for Fluorescence Note that the original QUINT workflow was generated by Yates and colleagues, and all credit for development of these programs goes to that team. References for each software are listed in the protocol.

  • Whole mount dissection and staining of enteric nervous system

    By on

    This protocol details whole mount dissection and staining of the enteric nervous system.

  • KOLF2.1 iPSCs AAVS1-NGN2

    By on

    iPSCs from British Caucasian male, modified with NEUROG2 using CRISPR/Cas9 in AAVS1 locus. Contains mutations in ARID2 (p.Pro197Hisfs*12) and COL3A1 (p.Gly1176Ser). Derived from skin fibroblasts of a 55-59-year-old male.

  • Gut mucosal cells transfer α-synuclein to the vagus nerve

    By on

    Published: These findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells. View original preprint.

  • HEK293::TMEM192-3xHA RB1CC1-/-

    By on

    HEK293::TMEM192-3xHA RB1CC1-/- PubMed=37757899; Characteristics: Using CRISPR/Cas9 TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope (from parent cell line). Knockout cell: Method=CRISPR/Cas9; 15574; RB1CC1. Transformant: NCBI_TaxID; 28285; Adenovirus 5. Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113. NCBI_TaxID=9606; ! Homo sapiens (Human) RRID:CVCL_C0I5 ! HEK293::TMEM192-3xHA Female Fetus Transformed cell line

  • HeLa::TMEM192-3xHA

    By on

    HeLa ::TMEM192-3xHA PubMed=37757899; Population: African American. Characteristics: Using CRISPR/Cas9 TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope (from parent cell line). Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18). Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002. NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma NCBI_TaxID=9606; ! Homo sapiens (Human) RRID:CVCL_0030 ! HeLa Female 30Y6M Cancer cell line

  • HEK293::TMEM192-3xHA RB1CC1-/- mNEON-YIPF4

    By on

    HEK293::TMEM192-3xHA RB1CC1-/- mNEON-YIPF4 PubMed=37757899; Characteristics: Using CRISPR/Cas9 TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope (from parent cell line). Characteristics: Using CRISPR/Cas9 YIPF4 was N-terminally tagged on both alleles with mNeonGreen (PubMed=37757899). Knockout cell: Method=CRISPR/Cas9; 15574; RB1CC1. Transfected with: UniProtKB; A0A1S4NYF2; mNeonGreen (derivative of Branchiostoma lanceolatum blFP-Y3). Transformant: NCBI_TaxID; 28285; Adenovirus 5. Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113. NCBI_TaxID=9606; ! Homo sapiens (Human) RRID:CVCL_D1KQ ! HEK293::TMEM192-3xHA RB1CC1-/- Female Fetus

  • Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms

    By on

    Zenodo archive contains post-sequence QC, taxonomic, and functional profiling data. Supplementary Code includes workflow and bioinformatic processing used in the manuscript. Raw sequences and metadata are on NCBI SRA under BioProject ID PRJNA834801.

  • Population fraction of Parkinson’s disease attributable to preventable risk factors

    By on

    R-based Posit project for replicating Parkinson's disease risk factor analysis. Includes data in 'input' folder, .Rproj file, renv lockfile, workflow scripts, and output scripts. Refer to README.md for more details.

  • Microbial amyloids in neurodegenerative amyloid diseases

    By on

    Published: Inhibiting microbial amyloids or their interactions with the host, may therefore represent a tangible target to limit various amyloid pathologies.

  • Characterizing dysbiosis of the Parkinson’s disease gut microbiome using shotgun metagenomics

    By on

    Parkinson's disease is a progressive neurodegenerative condition with altered gut microbiome composition. A study analyzed fecal samples from 490 PD patients and 234 healthy individuals to understand dysbiosis at a detailed level.

  • Nigrostriatal Tau Pathology in parkinsonism and Parkinson’s disease

    By on

    While Parkinson’s disease remains clinically defined by cardinal motor symptoms resulting from nigrostriatal degeneration, it is now appreciated that the disease commonly consists of multiple pathologies, but it is unclear where these co-pathologies occur early in disease and whether they are responsible for the nigrostriatal degeneration. For the past number of years, we have been studying a well-characterized cohort of subjects with motor impairment that we have termed mild motor deficits. Motor deficits were determined on a modified and validated Unified Parkinson’s Disease Rating Scale III but were insufficient in degree to diagnose Parkinson’s disease. However, in our past studies, cases in this cohort had a selection bias, as both a clinical syndrome in between no motor deficits and Parkinson’s disease, plus nigral Lewy pathology as defined post-mortem, were required for inclusion. Therefore, in the current study, we only based inclusion on the presence of a clinical phenotype with mild motor impairment insufficient to diagnose Parkinson’s disease. Then, we divided this group further based upon whether or not subjects had a synucleinopathy in the nigrostriatal system. Here we demonstrate that loss of nigral dopaminergic neurons, loss of putamenal dopaminergic innervation and loss of the tyrosine hydroxylase-phenotype in the substantia nigra and putamen occur equally in mild motor deficit groups with and without nigral alpha-synuclein aggregates. Indeed, the common feature of these two groups is that both have similar degrees of AT8 positive phosphorylated tau, a pathology not seen in the nigrostriatal system of age-matched controls. These findings were confirmed with early (tau Ser208 phosphorylation) and late (tau Ser396/ Ser404 phosphorylation) tau markers. This suggests that the initiation of nigrostriatal dopaminergic neurodegeneration occurs independently of alpha-synuclein aggregation and can be tau mediated.

  • Peripheral MC1R Activation Modulates Immune Responses and is Neuroprotective in a Mouse Model of Parkinson’s Disease

    By on

    Preprint: The present study investigates the impact of NDP-MSH, a synthetic melanocortin receptor (MCR) agonist that does not cross BBB, on the immune system and the nigrostriatal dopaminergic system in mouse model of PD.

  • Peripheral MC1R activation modulates immune responses and confers neuroprotection in a mouse model of Parkinson’s disease

    By on

    Dataset corresponding to the article, "Peripheral MC1R activation modulates immune responses and confers neuroprotection in a mouse model of Parkinson's disease."

Load More
Aligning Science Across Parkinson's
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.